Pharma.Aero Finalizes the In-Depth Assessment of the CEIV Pharma Certification Program Together with IATA

Pharma.Aero has just published the White Paper of the CEIV 2.0 Project representing a broader evaluation of the IATA’s CEIV Pharma Certification Program based on the direct input and insights of the Pharma.Aero global membership. The document presents the main conclusions and takeaways of an evaluation process that identified potential areas of improvements, with root causes and potential solutions for further actions.

Read here the White Paper of the CEIV 2.0 Project – Phase 1

The CEIV Pharma certification has become a quality standard over the years, with more than 300 companies being certified or re-certified at different locations around the globe (December 2022). But what does the industry feel about the impact of the CEIV Pharma certification on the day-to-day business? Did the certification meet the initial expectations over the years? What are the challenges that certified companies face in relation to this program?

The CEIV 2.0 Project started in September 2021 with the dissemination of two surveys to Pharma.Aero members, one for the pharma logistics providers, and one tailored for pharma manufacturers. The surveys aimed to identify various challenges that the companies are facing in relation with the CEIV Pharma certification program. The results of the surveys showed 7 areas of improvement which were further analyzed, one by one, over a series of 8 working sessions with Pharma.Aero members and IATA representatives. Throughout the working sessions, participants deep delved into each category, identifying probable root causes, and potential solutions for the 7 areas of improvements.

The project’s methodology, findings and conclusions were presented in a detailed, comprehensive Technical Report that Pharma.Aero shared with its members and IATA recently. The White Paper published now for the entire industry summarizes the main findings and offers a general overview of the project.

5 of the 15 clustered solutions that were identified will be the focus of a follow-up project to start soon, CEIV 2.0 – Phase 2: Implementation.

• Authority Endorsement – Seek endorsement from global health authorities to increase the credibility of the CEIV certification program
• Shipper Review Group – Obtain feedback on the CEIV Pharma checklist, audit guidelines/standards, and demonstrate the value of CEIV to the GDP
• Communications to the Pharmaceutical Community – Increase awareness and understanding of the CEIV Pharma certification program, through workshops, presentations and other events
• CEIV Pharma Database – Make audit results and improvements over time available to shippers
• Light Version of the CEIV Pharma for companies with limited resources

We would like to sincerely thank IATA for their trust in Pharma.Aero and collaboration. And to the Independent Validators who shared their expertise towards the development of the project.

Many thanks to the two project leads, Dnata and Brussels Airport, for their time and support.

Special thanks go to the 25 members and partners of Pharma.Aero for their valuable contribution and their participation in the project’s workshops: Airport Authority Hong Kong, Alha Group, BDP International, Brussels Airport, Cargo Service Centre, Cathay Pacific Airways, Changi Airport Group, Dallas Fort Worth Airport, DHL Global Forwarding, Dnata, Envirotainer, Expeditors, First Priority Cargo, GRU Airport, Kansai Airports, Latin America Cargo City, MSD Merck, Miami Airport, Mytigate, Pfizer, Qatar Airways, Tower Cold Chain, Turkish Airline, Validaide and Wiz.